Fulvestrant

Catalog No.S1191 Synonyms: ICI-182780, ZD 9238

Fulvestrant Chemical Structure

Molecular Weight(MW): 606.77

Fulvestrant is an estrogen receptor (ER) antagonist with IC50 of 0.94 nM in a cell-free assay.

Size Price Stock Quantity  
In DMSO USD 64 In stock
USD 70 In stock
USD 270 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

5 Customer Reviews

  • PTPH1 confers breast cancer cell sensitivity to fulvestrant. E and F, PTPH1 overexpression increases the growth inhibition by fulvestrant. PTPH1 was overexpressed by a Tet-on system or a stable transfection, and resultant cells were incubated with fulvestrant as indicated for about 2 weeks. Colony formed was stained and counted. Results shown are normalized to its own solvent control of Vector and PTPH1-overexpressed cells, respectively (means ± SD; n = 3–5) with insets showing PTPH1 overexpression. *, versus vector or no Tet cells for E and F.

    Mol Cancer Ther 2014 13(1), 230-8. Fulvestrant purchased from Selleck.

     

    Fulvestrant resistance induced by 6 different ZF-TFs. (A) Drug sensitivity of fulvestrant-selected MCF7 ZF-TF-transduced cells. MCF7 cells transduced with one of six different ZF-TF-expressing retroviruses selected first in puromycin (the transduction selection marker) and then in fulvestrant for 1 month were grown in the absence of fulvestrant for 7 days and then challenged with 100 nM fulvestrant or vehicle (0.1% ethanol) for 21 days followed by crystal violet staining and visualization. Data are representative of triplicate experiments.

    PLoS One 2011 6, e21112. Fulvestrant purchased from Selleck.

  • Fulvestrant resistance induced by 6 different ZF-TFs. (B and C) Growth curves of MCF7 and T47D cells in the presence and absence of fulvestrant. Comparison of cell growth rates (cell number, mean +/2 SEM, n = 8; time in days as indicated) of MCF7 and T47D cells stably transduced with control retrovirus or one of six different ZF-TF-expressing retroviruses (7, 19, 64, 70, 83 and 115) in the presence (blue line) or absence (pink line) of fulvestrant.

    PLoS One 2011 6, e21112. Fulvestrant purchased from Selleck.

    CDK4/6 inhibitor resistance promotes diminished ER expression and activity. (a and b) Proliferation of MCF-7 and MR cells in the presence of different concentrations of ICI (a) or 4-hydroxytamoxifen (4-OHT) (b) was measured by the alamarBlue assay and plotted as % inhibition of proliferation against log concentration of inhibitor. Each data point represents the average value±s.d. of six replicates obtained in three independent experiments. (c) MCF-7 and MR cells were treated with different concentrations of ICI, collected after 24 h and then immunoblotted with the indicated antibodies.

    Oncogene, 2017, 36(16):2255-2264. Fulvestrant purchased from Selleck.

  • A: Time dependent loss of MGMT activity in ERα-positive MCF7 and T47D tumor cells but not in ERα-negative MDAMB-468 cells after 1 μmol/L Fulvestrant treatment (upper panel). Concentration dependent inhibition of MGMT activity in MCF7 and T47D cells but not in MDA-MB-468 cells after a 72 hours exposure to fulvestrant (lower panel). The data represents the mean of two independent experiments in duplicate and the last time point (72 hours) as assessed by student's t-test was significant at P < 0.05. B: Decreased MGMT and ER-α protein levels in MCF7 cells after 48 hours and 72 hours fulvestrant exposure. ICI is fulvestrant, also called ICI-182,780. C: Decreased MGMT and ER-α protein levels in T47D cells after 48 hours and 72 hours fulvestrant exposure.

    J Biomed Res, 2016, 30(5):393-410. Fulvestrant purchased from Selleck.

Purity & Quality Control

Choose Selective Estrogen/progestogen Receptor Inhibitors

Biological Activity

Description Fulvestrant is an estrogen receptor (ER) antagonist with IC50 of 0.94 nM in a cell-free assay.
Targets
ER [1]
(Cell-free assay)
0.94 nM
In vitro

Fulvestrant is an effective inhibitor of the growth of ER-positive MCF-7 (with IC50 of 0.29 nM) but with no effect on the growth of ER-negative BT-20 human breast cancer cells. Fulvestrant causes accumulation of cells in G0/G1 and also reduces the proportion of cells capable of continued DNA synthesis. [1] Fulvestrant competitively inhibits binding of oestradiol to the estrogen receptor. Fulvestrant blocks nuclear localization of the ER through impairing receptor dimerisation, and energy-dependent nucleo-cytoplasmic shuttling. Because of the instability of fulvestrant-ER complex, the binding of Fulvestrant with ER finally results in accelerated degradation of the ER protein. [2] Fulvestrant (10 nM) not only decreases IGF-IR mRNA levels but also decreases the half-life. [3] Treatment with 100 μM Fulvestrant leads to a time dependent increase of TNFR1 and TRADD steady-state mRNA levels in MCF-7 cells. [4] Fulvestrant is capable of down-regulating androgen receptor expression and diminishes androgenic responses in LNCaP human prostate cancer cells. Fulvestrant also significantly attenuates R1881-stimulated growth by 70%. [5] Fulvestrant is able to modulate mitosis and cell death in immature cerebellar neurons via rapid activation of MAPK. [6]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF-7 M{PxRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVGxMlMuOTByMDDuUS=> NXG2PHp{PDhiaB?= NE\0NFNqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NUL2W2p4OjR7N{myPVQ>
MCF-7/LTED NInE[25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXqxMlMuOTByMDDuUS=> NFTo[3Y1QCCq MW\pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NUXv[nBmOjR7N{myPVQ>
HCC1428 M{PDTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\SNU4{NTFyMECgcm0> MWS0PEBp MUDpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NVXKVphHOjR7N{myPVQ>
HCC1428/LTED NFuzR4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXaNYN{OS5|LUGwNFAhdk1? M3z2b|Q5KGh? NE\CUHlqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NF3BZpQzPDl5OUK5OC=>
LCC1 MWrGeY5kfGmxbjDBd5NigQ>? MVexNFAhdk1? NWH3fFl2PDhvMUS0JIg> Mn3zZYN1cX[jdHXzJHVRWiC|aXfuZYxqdmd? NWrMVGpDOjR6NUiyO|c>
LCC9 MVXGeY5kfGmxbjDBd5NigQ>? M2e5fFExOCCwTR?= MUC0PE0yPDRiaB?= M4rkeYFkfGm4YYTld{BWWFJic3nncoFtcW6p MX6yOFg2QDJ5Nx?=
MCF-7  NInrcWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFX5dWgyODBibl2= M1riS|Uh\A>? Mkf5bY5pcWKrdIOgZ4VtdCCpcn;3eIghfG9iMUFvwKU> NXfPXYtEOjR6MUm1OVA>
mesangial  M3HvbWZ2dmO2aX;uJGF{e2G7 NI\IRlExNjFvMUCwJI5O MlXpOFghcA>? MWfzeZBxemW|c3XzJHRITi4QskGtbY5lfWOnZDD0fZBmKEmYIHPvcIxi\2Ww Ml;RNlQ4QTN4M{m=
Mesangial MYPGeY5kfGmxbjDBd5NigQ>? NUD4PZZ3OC5zLUGwNEBvVQ>? NWLqcYs3OC53IHi= NVfSS|lQcW6qaXLpeJMhXEeILd8yNU1qdmS3Y3XkJHNu[WR{IIDoc5NxcG:{eXzheIlwdiC4aXGgS3BGWg>? NYfzc4U2OjR5OUO2N|k>
ER+ MCF-7/2a NXXhb2RVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIP4W4NKSzVyPUCuNFA1KM7:TR?= MYWxOVMzPDh6NB?=
ER+ MCF-7 NFHzZlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXOxZZo3OjByIHi= MkTzTWM2OD1yLkKxJI5O NG\wTpcyPTN{NEi4OC=>
MCF-7  M1Hpc2Z2dmO2aX;uJGF{e2G7 MUCxNOKhdk4EoB?= NInUdmM4OiCq M3nlXZJmfmW{c3XzJJRp\SCnc4Tyc4dmdiCnZn\lZ5QpUUN3MDCxMlkhy5diMUFijLI6KE1r NWfnUGJIOjR7MEi2OVI>
MCF-7  NI\LSo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XaSGlEPTEEoH;mJIFxeHKxeHntZZRmdHliMjDuUS=> NETZW3czOzR2OEO0Oi=>
H1975  NFLuNpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjwN:Kh|ryP MX[xJI0> Mm\mbY5kemWjc3XzJJRp\SCpZX\peIlvcWJic3Xud4l1cX[rdImgc4YhUDF7N{WgZ4VtdHQEoB?= M3XGN|I1OjZ6OEGw
H1975 NH;ySGtHfW6ldHnvckBCe3OjeR?= MkSyN:Kh|ryP Mm\DNUBu NYDDWVREfXC{ZXf1cIF1\XNidHjlJIxmfmWuIH;mJGxmfC15Yx?= NIj0[ZozPDJ4OEixNC=>
MCF-7  M1LuWGZ2dmO2aX;uJGF{e2G7 NEe4dmUyODEkgJnuUeKh MmHRO|IhcA>? NVjlOI06emW4ZYLz[ZMhfGinIIDyc5Rm[3SrdnWg[YZn\WO2IH;mJGUzyqCrbjDj[YxtKGmwdnHzbY9v MVyyN|k{Pjd5Mx?=
MCF-7  MWHGeY5kfGmxbjDBd5NigQ>? MYexNFDjiImwTdMg MVqyOE81QCCq NGjwNHRn[WOrbHn0ZZRmeyCrbo\hd4lwdiC2aILveYdpKE2PUIOnJI1w\HWuYYTpc44> MnGxNlM6OzZ5N{O=
BT474-tet-shMED1 M3XwTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4ThV|AvOS13IN88US=> MnvyO{Bl M4W1TYlv[3KnYYPld{AsTG:6IHnu[JVk\WRiY3XscEBl\WG2aDDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NWXsR2FvOjN7M{[yN|Q>
ZR75-1-tet-shMED1  NFvqUoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUGwMlEuPSEQvF2= MljLO{Bl NFHhd2RqdmO{ZXHz[ZMhM0SxeDDpcoR2[2WmIHPlcIwh\GWjdHigbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NHzMRXczOzl|NkKzOC=>
MCF-7-tet-shMED1 NELibVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnPUW1SOC5zLUWg{txO MWK3JIQ> MXLpcoNz\WG|ZYOgL2RwgCCrbnT1Z4VlKGOnbHyg[IVifGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M{TyPVI{QTN4MkO0
HepG2  NHjQb3BHfW6ldHnvckBCe3OjeR?= NYm4ZVFtOC5yMT2xNEDPxE1? M1LlW|E5KGkEoB?= M36yUIFkfGm4YYTld{B1cGViRWLFMY1m\GmjdHXkJJRz[W6|Y4LpdJRqd25ib3[gRWYzTVJ? M1X6clI{PzN|MUi4
MCF-7L  NYPQ[nlSTnWwY4Tpc44hSXO|YYm= M{XyPVExOCCwTdMg M4rsT|ExKG2rbj:yOEBpNzR6IHi= MlfBdoV{fWy2czDpckBGT0[ULDDISXIzKGGwZDDISXI{KHCqb4PwbI9zgWyjdHnvckBifCCycn;sc45o\WRiZYjwc5N2emV? M4PCVFI{Pjh4NEG2
MCF-7L  NUfhdm81TnWwY4Tpc44hSXO|YYm= M2PSd|ExOCCwTdMg MYW0PEBp NUToOVA6cW6mdXPld{B2eHKnZ4XsZZRqd25ib3[gcXJPSSCxZjDFS2ZTKGyrZ3Hu[EBJSi2HR1[= MX2yN|Y5PjRzNh?=
MCF-7L MX7GeY5kfGmxbjDBd5NigQ>? MnPkNVAxKG6PwrC= MlraOFghcA>? NXHpW213cW6mdXPld{BGT0[UIH\hcYltgSCvZX3i[ZIh[WO2aY\heIlwdiC{ZYH1bZJm\CCHUh?= MVqyN|Y5PjRzNh?=
C4-12  NFf2cVVHfW6ldHnvckBCe3OjeR?= M2TSXFExOCCwTdMg M2HaWFQ5KGh? M1L2ZYlv\HWlZYOgSWdHWiCoYX3pcJkhdWWvYnXyJIFkfGm4YYTpc44hemWzdXny[YQhTVJ? M3;kelI{Pjh4NEG2
MCF-7L NXGycWNjTnWwY4Tpc44hSXO|YYm= MXexNFAhdk4EoB?= NY\CbXZzOjRiaB?= NWmyd5RFcW6mdXPld{BGT0[UIIDoc5NxcG:{eXzheIlwdiC{ZYH1bZJm\CCKQj3FS2Yh\nWwY4Tpc44> NWLjT|g2OjN4OE[0NVY>
MMQ  NIrtd3NHfW6ldHnvckBCe3OjeR?= NHzQb2UxNTZ{NTDuUS=> M3rt[FczKGh? NXLjUWlX\G:5bj3y[Yd2dGG2ZYOgeIhmKGW6cILld5Nqd25ib3[g[ZN1em:pZX6gdoVk\XC2b4Kt{tEhMEWUzsGp NE\POngzOzV{M{O1Oy=>
H1975  M4K5O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnINE4{OTJ3LUGwJO69VQ>? NUjrd2xyPiCm MWnpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MYGyN|M6QTl3Nx?=
H1975  NF\OO2dCeG:ydH;zbZMhSXO|YYm= NY\aZms4OjByIH7N MXO3NkBp M3XjdoVvcGGwY3XzJIVzdG:2aX7pZkBqdmS3Y3XkJIFxd3C2b4Ppdy=> Mn7hNlM{QTl7NUe=
MCF-7  MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrrNVAwOTByL{GwNFAhdk1? M3PQUFIwPC94IHS= NF;SVYxFVVOR MYnpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJIRwe2VvIHHu[EB1cW2nLTDk[ZBmdmSnboSgcYFvdmW{ MnzTNlM{OTN3ME[=
MCF-7  MkXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\X[FExOCCwTR?= NF3Qbo81KGR? MlzSSG1UVw>? MmO3bY5lfWOnczDhJIhq\2incjDwdo9xd3K2aX;uJI9nKGOnbHzzJIlvKHSqZTDHNUBxcGG|ZdMg MWKyN|MyOzVyNh?=
MLO-Y4  NI\KN3lHfW6ldHnvckBCe3OjeR?= NFnUbm8yyqEQvF2= MYGxJIg> MYfpcohq[mm2czDFNk1qdmS3Y3XkJGN5PDNiZYjwdoV{e2mxbh?= MlnTNlMzPDdyNUe=
MCF-7 MmfuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXixNFAhdk1? MkjVOFghcA>? NWHMZ3hU[WK{b3fheIV{KHSqZTDwdo9tcW[ncnH0bZZmKGWoZnXjeEBw\iCvb3TldoF1\SCwaYTyc5NifGm4ZTDzeJJme3N? M3GyO|I{OjF4N{S0
TG1-1  MVXGeY5kfGmxbjDBd5NigQ>? NGTpSlgyyqEQvF2= NHnWdowzPCCq NFTPVWNi[nKxZ3H0[ZMhTTMEoHnu[JVk\WRiYXPjeY12dGG2aX;uJI9nKEiLRj2x{tE> NFu1XogzOzB6OE[wOy=>
TG1-1  MknYSpVv[3Srb36gRZN{[Xl? NF3iVHAyyqEQvF2= Moj1NlQhcA>? NYHnbGV5[WK{b3fheIV{KEV{wrDpcoR2[2WmIHHjZ5VufWyjdHnvckBw\iCSSUPL M4\2[FI{ODh6NkC3
MCF7 NEnGOIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXSxNFAhdk1? MUG0PEBp NH7Zbllt\WGmczD0c{BiKHOrbXnsZZIhdG:|czDpckB{fXK4aY\hcEBieyC5aYToJIRwgG:{dXLpZ4lvKGGub37l M2nFNVI{ODd5MkS5
MCF7 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\EVFExOCCwTR?= MXq0PEBp NF;pe4RmdmijbnPld{BvfXSuaX6tcYVlcWG2ZXSgZ4VtdCCmZXH0bC=> NVLLOY4xOjNyN{eyOFk>
MCF-7  NWXqfnF4TnWwY4Tpc44hSXO|YYm= M1PrUVYhcA>? MnXwSG1UVw>? NGLQRopifHSnboXheIV{KHSqZTDmcJVlcW:6b37pcE0hd3JiZnXubIV5[W2rZD3pcoR2[2WmIHnuZ5Jm[XOnIHnuJI1qWi1{MTDlfJBz\XO|aX;u NX\WPI9sOjNyNUKwN|Y>
MCF-7 NYLMe|Y1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfGO5EyODBibl2vNUDPxE1? NGDuNGI2KGR? MlrHbY5pcWKrdIOgeIhmKHO2aX31cIF1cW:wIH;mJFE4|rJvZYP0doFlcW:u MnnyNlI6QDJ5NkW=
MCF-7 M3PHSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3jXlVVOTByIH7N M{jlUlUh\A>? NILkSHZqdmirYnn0d{B1cGVic4TpcZVt[XSrb36gc4Yh\nW|YYLp[YxqdiCK MVKyNlk5Ojd4NR?=
1471.1 NXzmNZp6TnWwY4Tpc44hSXO|YYm= M2D2[|ExOCCwTR?= M1;DWlEhcA>? NI\zbpNGfE:KwrC= NX[2PVdFfGGtZYOgc44h[SCydX7jeIF1\SC|dHHpcolv\yCyYYT0[ZJv MX6yNlg3QTFyNh?=
MCF-7 NEj6eXlHfW6ldHnvckBCe3OjeR?= NEDZVGQyODBibl2= MVSxJIg> NHK5ZmRGfE:KwrC= NG\CS2t1[WunczDvckBiKHC3bnP0ZZRmKHO2YXnubY5oKHCjdITldo4> NUHHOJRMOjJ6NkmxNFY>
HeLa MUHGeY5kfGmxbjDBd5NigQ>? NFGzfG8yODBibl2= NWPwT21kOSCq NGm4PIJGfE:KwrC= NVfycI9qfGGtZYOgc44h[SCydX7jeIF1\SC|dHHpcolv\yCyYYT0[ZJv MXeyNlg3QTFyNh?=
COS-7  M{jLXWZ2dmO2aX;uJGF{e2G7 M{n1cVExOCCwTR?= M{nxU|EhcA>? M3LHTGV1V0kEoB?= M2\4UJRic2W|IH;uJIEheHWwY4TheIUhe3SjaX7pcocheGG2dHXyci=> M4PhVlIzQDZ7MUC2
BG1L-OHTLT  MoHKSpVv[3Srb36gRZN{[Xl? NUGwZW5lOTEEoH7N MkjHNlTDqGkEoB?= MXrpcohq[mm2czDFVu6yKGW6cILld5Nqd25? M36yZlIzPjV{NUW4
BG1L-ICILT Mn3mSpVv[3Srb36gRZN{[Xl? MVqxNOKhdk1? NFjoOJEzPMLiaNMg M3;UN4lvcGmkaYTzJGVT|rFiZYjwdoV{e2mxbh?= MlvDNlI3PTJ3NUi=
PC-9 M2TUSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDUR28xNjByMz2zNEDPxE1? NVzIeGpEPDhiaB?= MXzpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NHn4O5MzOjV4ME[zOC=>
H1650 NF\BUWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHWNE4xODNvM{Cg{txO MlK5OFghcA>? NFrUWHFqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NY\nNGZpOjJ3NkC2N|Q>
H1975 NIPrVZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjlNE4xODNvM{Cg{txO M4\0VlQ5KGh? NEj2fnBqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M2jZfVIzPTZyNkO0
H1975 NXHaWplnTnWwY4Tpc44hSXO|YYm= M1LWVFPDqM7:TR?= MkHTN{Bp MmDDZYJzd2ejdHXzJJRp\SCyaH;zdIhwNUWJRmKgbY5lfWO2aX;uJIJ6KGW|dILv[4Vv M2jIeFIzPTZyNkO0
H1975 NE\Ufm5HfW6ldHnvckBCe3OjeR?= M4XxPFPDqM7:TR?= M3\xOlch\A>? MXXpcoR2[2W|IFXHSnIh\XiycnXzd4lwdg>? M2TmbVIzPTZyNkO0
HTR-8 NX;tN5o5TnWwY4Tpc44hSXO|YYm= NFjiXIsyyqEQvF2= M1fNZ|EuPDhiaB?= NYXCTWhE\G:5bj3y[Yd2dGG2ZYOgeIhmKGW6cILld5Nqd25ib3[gTWdHSlB5IH3SUmE> MUCyNlM5OzFzMR?=
JEG-3 NHHEdGlHfW6ldHnvckBCe3OjeR?= NUHy[2FCOcLizszN NFnhN4kyNTR6IHi= NWrpe2Rn\G:5bj3y[Yd2dGG2ZYOgeIhmKGW6cILld5Nqd25ib3[gTWdHSlB5IH3SUmE> MUSyNlM5OzFzMR?=
Huh7 MnfPSpVv[3Srb36gRZN{[Xl? NVLDUWZrPTEEoN88US=> MnHrOFghcA>? NVvQUGs{cW6qaXLpeJMh\2WwaYP0[YlvNW2nZHnheIVlKFCRTkGgeJJidnOjY4TpeoF1cW:w MVKyNlMxPDJ7Nh?=
201T MoSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPacow2KM7:TR?= NV22UZpzPzJiaB?= M4XlVIlvcGmkaYTzJINmdGxiZ4Lve5RpKHOrZ37p[olk[W62bImgZ49u[mmwZXSge4l1cCC4YX7k[ZRidmmk NHnEWmEzOjJ3OES3Oi=>
A549  NW\wNpVzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnMOUDPxE1? MoW0O|IhcA>? NYexNW9VcW6qaXLpeJMh[2WubDDndo94fGhic3nncolncWOjboTsfUBkd22kaX7l[EB4cXSqII\hcoRmfGGwaXK= NVLmd45sOjJ{NUi0O|Y>
MCF-7 MWnGeY5kfGmxbjDBd5NigQ>? Mon1NeKh|ryP MY[yOEBpyqB? M{S4NoRwf26{ZXf1cIF1\XNiRWKg[ZhxemW|c3nvckBqdmS3Y3XkJIJ6KDRvT1itWEDDqA>? MmP6NlIxPDl|MU[=
HCC-1428 M2\neGZ2dmO2aX;uJGF{e2G7 M1LwfFHDqM7:TR?= MVyyOEBpyqB? Mnnl[I94dnKnZ4XsZZRmeyCHUjDlfJBz\XO|aX;uJIlv\HWlZXSgZpkhPC2RSD3UJOKh NXvXdlRCOjJyNEmzNVY>
MDA-361 MUTGeY5kfGmxbjDBd5NigQ>? NYrkXWQ5OcLizszN MVSyOEBpyqB? M33RWoRwf26{ZXf1cIF1\XNiRWKg[ZhxemW|c3nvckBqdmS3Y3XkJIJ6KDRvT1itWEDDqA>? NEfTV5EzOjB2OUOxOi=>
ZR75-1 MXfGeY5kfGmxbjDBd5NigQ>? MUOxxsDPxE1? MUGyOEBpyqB? NHL6VFBld3ewcnXneYxifGW|IFXSJIV5eHKnc4Ppc44hcW6mdXPl[EBjgSB2LV;IMXQhyqB? MWqyNlA1QTNzNh?=
MCF-7 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDTNYoxOcLizszN MUS1MVExKGR? M2[0WZN2eHC{ZYPz[ZMhTTJvaX7keYNm\CCpcn;3eIghcW6qaXLpeIlwdg>? M4roeFIzODR7M{G2
HCC-1428 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fSTFHDqM7:TR?= NHrsU3k2NTFyIHS= NWHYT|VXe3WycILld5NmeyCHMj3pcoR2[2WmIHfyc5d1cCCrbnjpZol1cW:w M2L5WlIzODR7M{G2
MDA-361 NYL6XoRpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELvSXcyyqEQvF2= NHHWToE2NTFyIHS= MoLCd5VxeHKnc4Pld{BGOi2rbnT1Z4VlKGe{b4f0bEBqdmirYnn0bY9v M3rVR|IzODR7M{G2
ZR75-1 M1SwV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoC3NeKh|ryP NUL0cFVvPS1zMDDk MVrzeZBxemW|c3XzJGUzNWmwZIXj[YQh\3Kxd4ToJIlvcGmkaYTpc44> MUSyNlA1QTNzNh?=
MCF-7/AC-1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTLNE0xNjJizszN MkLEOkBl MVHpcohq[mm2czDj[YxtKGe{b4f0bEBud2Snc4TsfS=> MnzFNlIxPDJ5OUK=
MCF7 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHTNVAhyrWP NGf3eI41QCCq MYXpcoR2[2W|IHPlcIwhcW6qaXLpeIlwdiC5aHnjbEBk[W5iYnWg[Y5p[W6lZXSgZpkh\mmkcn;icIF{fHN? M{S0UFIzODRzOEi3
MMQ M2HJ[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLQN5drOC14MkWgcm0> M1HXZ|czKGh? MmPwdJJw\HWlZYOgd5RifGm|dHnjZYxtgSC|aXfubYZq[2GwdDDpcohq[mm2aX;uJI9nKGOnbHygdJJwdGmoZYLheIlwdsLi MnPNNlIxOTVzMEG=
MMQ MofWSpVv[3Srb36gRZN{[Xl? MUGwMVYzPSCwTR?= MV63NkBp NIHoW3Nxem:mdXPld{BiKHO2YYTpd5Rq[2GubImgd4lodmmoaXPhcpQtKGSxc3Wt[IVx\W6mZX70JJJm\HWldHnvckBqdiCSUlygd4VkemW2aX;u MUOyNlAyPTFyMR?=
MCF7 M2LrdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fJcVAuOSEQvF2= MlHNNlQuOTJyIHi= NWnTVXFDcW6qaXLpeJMhfGinIHfyc5d1cCCxZjDNR2Y4NVmELUJCpC=> MmH0NlE5PjN{NUi=
HepG2 MnvuRZBweHSxc3nzJGF{e2G7 NUWxcXg2OC5zwrFOwG0> NHnTdlYzPCCq NIPMNWVi[m:uaYPo[ZMhfGinIHXzeJJw\2WwLXnu[JVk\WRidYCtdoVofWyjdHnvckBw\iCjcH;BTUBidmRiYYDvUS=> M4DsNlIyQDF4MkOz
MCF7–iFR3 M2rLeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFWxT|YzOC1zMECgcm0> NWnidHh6QTZiaB?= NHnSRVlmdmijbnPld{BCWC2rbnT1Z4VlKGOnbHyg[5Jwf3SqIHnubIljcXSrb36= NUnFbWVJOjF5OUK4PFk>
MCF7S MXrGeY5kfGmxbjDBd5NigQ>? M3jwO|HDqM7:TR?= M4TLW|Q5KGh? NXOz[WZX\G:5boLl[5Vt[XSnczDveoVz[WyuIFXS{tEheHKxdHXpckBt\X[nbIO= NEfjdFAzOTV|M{G5OS=>
MCF7 NUf0fIp6TnWwY4Tpc44hSXO|YYm= M2nYd|HDqM7:TR?= MVW0PEBp M{PBcoRwf26{ZXf1cIF1\XNib4\ldoFtdCCHUt8xJJBzd3SnaX6gcIV3\Wy| MWSyNVU{OzF7NR?=
MCF7S M3y1UGZ2dmO2aX;uJGF{e2G7 MmrpNeKh|ryP MV:3JIQ> M2Xmd4F1fGWwdXH0[ZMhfHWvb4LzdIhmemViZn;ycYF1cW:wIHHu[EBxem:uaX\ldoF1cW:w NXjHXI1pOjF3M{OxPVU>
MCF7S MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvxWWoxNjVxMTFOwG0> NYHQWFROPyCm NHrCU|ZFVVOR NUi4d5V3\GWlcnXhd4V{KGOnbHyg[Zhx[W6|aX;u NWf3eldROjF3M{OxPVU>
T47D  NHu2OW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PvV|Qhdk1? NVjxRYx1PDBiaB?= NHfhZmZ{fXCycnXzd4V{KGOnbHyg[5Jwf3SqIH3v[IVz[XSnbIm= NWXr[WpzOjF2OECzPVE>
BT474  MnLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1HzdFQhdk1? M3;DU|QxKGh? MkjTd5VxeHKnc4Pld{Bk\WyuIHfyc5d1cCCvb3TldoF1\Wy7 NXvSXodLOjF2OECzPVE>
T47D  NUTudnF4TnWwY4Tpc44hSXO|YYm= M4XKdlExKG6P NXzuVJV4PDBiaB?= NXLvfYpp\G:5boLl[5Vt[XSnczDFVu6yKHC{b4TlbY4> NE\nT5IzOTR6MEO5NS=>
BT474  MnOxSpVv[3Srb36gRZN{[Xl? M4LMXFExKG6P NHPqeVQ1OCCq NEjlUoNld3ewcnXneYxifGW|IFXS{tEheHKxdHXpci=> NEL3SWgzOTR6MEO5NS=>
MCF7 NHLzZ2RHfW6ldHnvckBCe3OjeR?= M{\HZ|ExOCCwTR?= M1T0blch\A>? M4nmTZJm\HWlZYOgSXLPuSCneIDy[ZN{cW:wIIPp[45q\mmlYX70cJk> NEm2W5MzOTN7NkC5OC=>
T47D  MlfSSpVv[3Srb36gRZN{[Xl? NIXwbZUyODBibl2= Ml3EO{Bl MlPSdoVlfWOnczDFVu6yKGW6cILld5Nqd25ic3nncolncWOjboTsfS=> MmfvNlE{QTZyOUS=
BT474  NGCwdo9HfW6ldHnvckBCe3OjeR?= MV[xNFAhdk1? MnW0O{Bl Mm[wdoVlfWOnczDFVu6yKGW6cILld5Nqd25ic3nncolncWOjboTsfS=> MVyyNVM6PjB7NB?=
MDAMB361 NUS1RmhqTnWwY4Tpc44hSXO|YYm= NWHkPZlzOTByIH7N M4HqZ|ch\A>? NUO2dXVKemWmdXPld{BGWs7zIHX4dJJme3Orb36gd4lodmmoaXPhcpRtgQ>? Mkn5NlE{QTZyOUS=
MCF7 NYfRN4cyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVGwMlAyNTFizszN NWToNphuPyCm NEXUfmVz\WS3Y3XzJINmdGxiZ4Lve5RpKHOrZ37p[olk[W62bIm= MmK5NlE{QTZyOUS=
T47D  MlXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVewMlAyNTFizszN MX[3JIQ> M3\uN5Jm\HWlZYOgZ4VtdCCpcn;3eIghe2mpbnnmbYNidnSueR?= NXPBS3dQOjF|OU[wPVQ>
BT474  Mk\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUWwMlAyNTFizszN M3XJeVch\A>? NYm1SWhzemWmdXPld{Bk\WyuIHfyc5d1cCC|aXfubYZq[2GwdHz5 MYmyNVM6PjB7NB?=
MDAMB361 M4XsVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTZe3dWOC5yMT2xJO69VQ>? NWPEPYF5PyCm NYrONJRsemWmdXPld{Bk\WyuIHfyc5d1cCC|aXfubYZq[2GwdHz5 M3nPXlIyOzl4MEm0
MCF7 Mmr3SpVv[3Srb36gRZN{[Xl? M1\PR|ExOCCwTR?= M{\Jblch\A>? NXW4OoNlcW6mdXPld{Bw\iCHcnLCN{BidmRiRYLiRlQhemWlZYD0c5Ih\XiycnXzd4lwdiCjbnSgd4lodmGubHnu[y=> NXzWRotoOjF|OU[wPVQ>
T47D  NULlRWFWTnWwY4Tpc44hSXO|YYm= MkLSNVAxKG6P MkTYO{Bl NH72dldqdmS3Y3XzJI9nKEW{YlKzJIFv\CCHcnLCOEBz\WOncITvdkBmgHC{ZYPzbY9vKGGwZDDzbYdv[WyuaX7n M1\aRVIyOzl4MEm0
BT474  M2nqdWZ2dmO2aX;uJGF{e2G7 MnHpNVAxKG6P M1X1O|ch\A>? NG\oboNqdmS3Y3XzJI9nKEW{YlKzJIFv\CCHcnLCOEBz\WOncITvdkBmgHC{ZYPzbY9vKGGwZDDzbYdv[WyuaX7n MVmyNVM6PjB7NB?=
MDAMB361 NWXEd4NqTnWwY4Tpc44hSXO|YYm= NG[xTIkyODBibl2= Ml33O{Bl MXHpcoR2[2W|IH;mJGVz[kJ|IHHu[EBGemKENDDy[YNmeHSxcjDlfJBz\XO|aX;uJIFv\CC|aXfuZYxtcW6p MVeyNVM6PjB7NB?=
MCF7 NV;xfIJkTnWwY4Tpc44hSXO|YYm= NGjCc|IyOCCwTR?= M2\EbFk3KGh? M2\u[IRwf26{ZXf1cIF1\XNiRWKg[ZhxemW|c3nvcuKh NWrZPIZmOjF|N{izN|M>
MDA-MB-231 MUTGeY5kfGmxbjDBd5NigQ>? NH3md5UyOCCwTR?= NFrycHk6PiCq Mn73[I94dnKnZ4XsZZRmeyCHUjDlfJBz\XO|aX;uxsA> MlvrNlE{Pzh|M{O=
SK-BR-3 MnXJSpVv[3Srb36gRZN{[Xl? M1vvO|ExKG6P NE\OU4c6PiCq M4PUe4Rwf26{ZXf1cIF1\XNiRWKg[ZhxemW|c3nvcuKh NGDuV4UzOTN5OEOzNy=>
MCF-7 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXqxNFAhdk1? NIrINVM4Oi97NjDo MXXjZZV{\XNiY3XscEBkgWOuZTDhdpJme3R? MVSyNVI6QTh4Mh?=
MMQ NH;GclFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfLUlVUOC5yMEitOlI2KG6P NVS1e2hbPzJiaB?= Mm[xbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nLTDhcoQh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MXWyNFcxODd3NR?=
MMQ Mne2SpVv[3Srb36gRZN{[Xl? NYS1OohWOC5yMEitOlI2KG6P NVvWXXc3PzJiaB?= MomxbY5pcWKrdIOgVHJNKHOnY4LleIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M1;6ZlIxPzByN{W1
MMQ MWLGeY5kfGmxbjDBd5NigQ>? NETPRY8xNjB2LU[yOUBvVQ>? MV[3NkBp M1LQS4lvcGmkaYTzJGVT|rFiZYjwdoV{e2mxbh?= NX7WdVVWOjB5MEC3OVU>
MMQ NFH6VlVHfW6ldHnvckBCe3OjeR?= NEHLRm0xNjB2LU[yOUBvVQ>? MlTLO|IhcA>? M2LtRpVxemWpdXzheIV{KFSJRt8yN{BidmRiVFfG{tJTUUliZYjwdoV{e2mxbh?= Mon0NlA4ODB5NUW=

... Click to View More Cell Line Experimental Data

In vivo Fulvestrant is devoid of uterotropic activity, and when co-administered with estradiol, it effectively blocks the uterotropic action of estradiol with ED50 of 0.06 mg/kg/day s.c. in immature female rats. A single s.c. injection of 5 mg of Fulvestrant suspension blocks completely the growth of MCF-7 xenografts. The growth of transplants of the BrlO human breast tumor is also suppressed effectively by 10 μM Fulvestrant. [1] Fulvestrant (10 mg/rat, s.c.) reduces the androgen receptor expression, ERK1/2 phosphorylation and cell proliferation in the rat ventral prostate. [7] Fulvestrant also displays anti-angiogenesis in the chick egg chorioallantoic membrane. [8]

Protocol

Cell Research:[1]
+ Expand
  • Cell lines: MCF-7 breast cancer cells
  • Concentrations: 2.9 nM
  • Incubation Time: 5 days
  • Method: MCF-7 cells are cultured in multiwell plates (24-well, seeding density 4 × 104) in minimal essential medium containing phenol red, insulin (10 μg/mL), and 5% charcoal-stripped fetal calf serum without additional estradiol. Fulvestrant and/or estradiol are added in fresh medium 2 days after seeding. Cultures are maintained for 5 days with one further medium change and growth is assessed by measurement of total cell protein at the beginning and end of treatment and compared with that of controls treated with ethanol (0.1%) alone.
    (Only for Reference)
Animal Research:[6]
+ Expand
  • Animal Models: The human breast cancer xenografts MCF-7 in nude mice
  • Formulation: 50 mg/mL in arachis oil
  • Dosages: 5 mg/mouse
  • Administration: s.c. injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (164.8 mM)
Ethanol 100 mg/mL warmed (164.8 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+95% Corn oil
For best results, use promptly after mixing.
30mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 606.77
Formula

C32H47F5O3S

CAS No. 129453-61-8
Storage powder
in solvent
Synonyms ICI-182780, ZD 9238

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01797120 Active, not recruiting Metastatic Breast Cancer PrECOG, LLC.|Novartis May 31, 2013 Phase 2
NCT01633060 Active, not recruiting Metastatic Breast Cancer Novartis Pharmaceuticals|Novartis October 3, 2012 Phase 3
NCT03007979 Not yet recruiting Breast Cancer|Breast Carcinoma|Cancer of Breast|Malignant Tumor of Breast Washington University School of Medicine February 28, 2017 Phase 2
NCT03024580 Not yet recruiting Breast Neoplasm Instituto Nacional de Cancer, Brazil|Cancer Research UK Cambridge Institute March 2017 Phase 2
NCT02947685 Not yet recruiting HER-2 Positive Breast Cancer|Estrogen Receptor Positive Breast Cancer Alliance Foundation Trials, LLC.|Pfizer|German Breast Group (GBG)|Fondazione Michelangelo|PrECOG, LLC.|The Australia and New Zealand Breast Cancer Trials Group (ANZBCTG)|Alliance Foundation Trials Biorepository - Washington State University|Alliance Foundation Trials Central Imaging Core Lab - Ohio State University|Mastering Breast Cancer Initiative, LLC|Mayo Clinic Statistics and Data Center|INC Research|SOLTI Breast Cancer Research Group February 2017 Phase 3
NCT02983604 Recruiting Advanced Estrogen Receptor Positive HER2- Breast Cancer Gilead Sciences January 2017 Phase 1|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Is there any information for the half-life of fulvestrant (Cat No.S1191)?

  • Answer:

    S1191, is about 13.5 to 18.5 hours in vivo: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2750771/. The half life of these compounds in cell culture might be different and we generally recommend replenishing with fresh drug every 24-48 hours.

Estrogen/progestogen Receptor Signaling Pathway Map

Estrogen/progestogen Receptor Inhibitors with Unique Features

Related Estrogen/progestogen Receptor Products

Tags: buy Fulvestrant | Fulvestrant ic50 | Fulvestrant price | Fulvestrant cost | Fulvestrant solubility dmso | Fulvestrant purchase | Fulvestrant manufacturer | Fulvestrant research buy | Fulvestrant order | Fulvestrant mouse | Fulvestrant chemical structure | Fulvestrant mw | Fulvestrant molecular weight | Fulvestrant datasheet | Fulvestrant supplier | Fulvestrant in vitro | Fulvestrant cell line | Fulvestrant concentration | Fulvestrant nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID